1. Medtech Insight
  2. >>Business
  3. >>Deals

'Unmet Needs And Thinking Big,' Inari Buys LimFlow For $250m To Add CLTI Treatment

 
• By Reed Miller

LimFlow recently earned FDA approval for its transcatheter deep-vein arterialization system for the treatment of chronic limb-threatening ischemia. Inari, which has previously focused on venous thromboembolism, believes LimFlow's total addressable market could be worth over $4bn annually, with no direct competition in sight.

Vein becoming artery with LimFlow crossing stent
Vein becoming artery with LimFlow crossing stent • Source: LimFlow SA

Inari Medical plans to pay up to $415m for Paris-based LimFlow SA to add the LimFlow transcatheter deep-vein arterialization system to its portfolio of peripheral vascular interventional devices, the companies announced on 1 November.

“Our ethos and mission are focused on addressing significant unmet needs and thinking big,” Inari CEO Andrew Hykes said during Inari’s third-quarter 2023 earnings calls on 1 November

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 
• By Natasha Barrow

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

More from Business